| Name | Title | Contact Details |
|---|
Identity Graphic Design is a Warren, MI-based company in the Business Services sector.
Ultima Genomics is unleashing the power of genomics at scale. Our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biologys complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultimas revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.
CQ fluency is a New Jersey-based translation and localization company founded in 2000. It specializes in culturally intelligent language solutions for regulated industries, particularly healthcare and government. With a team of 201–500 employees, the company operates as a Minority Business Enterprise (MBE) and is dedicated to improving health equity and fostering linguistic inclusivity worldwide. The company offers a wide range of language services, including translation and localization in over 300 languages, multicultural consultancy, interpretation, transcription, e-Learning localization, and regulatory support. CQ fluency utilizes advanced technology to enhance human translations, ensuring efficiency and scalability. Its workflows are designed for agility, with dedicated linguists and project managers available around the clock. CQ fluency collaborates with healthcare organizations, government entities, academic institutions, and Fortune 500 companies. Its mission is to create a linguistically equitable world, ensuring individuals are understood in their preferred language and improving accessibility and inclusion across diverse communities.
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN
Prestige Properties is a Stevensville, MD-based company in the Business Services sector.